Kallikrein 4 is expressed in malignant mesothelioma - Further evidence for the histogenetic link between mesothelial and epithelial cells

Diagnostic Cytopathology

Volumn 35, Issue 2, 2007, Pages 80-84

  Davidson, Ben ^a   Xi, Zhijun ^b   Saatcioglu, Fahri ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Breast carcinoma; Effusion; Malignant mesothelioma; Proteolysis

Indexed keywords

KALLIKREIN; KALLIKREIN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST ADENOCARCINOMA; COMPARATIVE STUDY; EFFUSION; EPITHELIUM CELL; FEMALE; HISTOGENESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; OVARY ADENOCARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; SOLID TUMOR; TISSUE SECTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASCITIC FLUID; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT;

EID: 33846946151     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20588     Document Type: Article

References (23)

1. Yousef GM, Diamandis EP. The new human kallikrein gene family: Structure, function, and association to disease. Endocr Rev 2001;22:184-204.
2. Clements J, Hooper J, Dong Y, Harvey T. The expanded human kallikrein gene family: Genomic organisation, tissue-specific expression and potential functions. Biol Chem 2001;382:5-14.
3. Nelson PS, Gan L, Fergusson C. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999;96:3114-3119.
4. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999;59:4252-4256.
5. Korkmaz KS, Korkmaz CG, Pretlow TG, Saatcioglu F. Distinctly different gene structure of KLK4/KLK-L1/Prostase/ARM1 compared with other members of the Kallikrein family: Intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol 2001;7:435-445.
6. Stephenson SA, Verity K, Ashworth LK, Clements JA. Localization of a new prostate-specific antigen-related serine protease gene. KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999;274:23210-23214.
7. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002;48:1232-1240.
8. Day CH, Fanger GR, Retter MW, et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 2002;21:7114-7120.
9. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365-2370.
10. Matsumara M, Bhatt AS, Andress D, et al. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005;62:1-13.
11. Veveris-Lowe TL, Lawrence MG, Collard RL, et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:631-643.
12. Obiezu CV, Michael IP, Levesque MA, Diamandis EP. Human kallikrein 4: Enzymatic activity, inhibition, and degradation of extracellular matrix proteins. Clin Chem 200;387:749-759.
13. Davidson B, Xi Z, Klokk TI, et al. Kallikrein 4 expression is upregulated in ovarian carcinoma cells in effusions. Am J Clin Pathol 2005;123:360-368.
14. Davidson B, Nielsen S, Christensen J, et al. The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-1412.
15. Edwards JG, McLaren J, Jones JL, Waller DA, O'Byrne KJ. Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer 2003;88:1553-1559.
16. Trupiano JK, Geisinger KR, Willingham MC, et al. Diffuse malignant mesothelioma of the peritoneum and pleura, analysis of markers. Mod Pathol 2004;17:476-481.
17. Davidson B, Reich R, Lazarovici P, et al. Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer 2004;44:159-165.
18. Davidson B, Vintman L, Zcharia E, et al. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma. Clin Exp Metastasis 2004;21:469-476.
19. Kleinberg L, Flørenes VA, Skrede M, et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 2006;449:31-39.
20. Davidson B, Lazarovici P, Ezersky A, et al. Expression levels of the NGF receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients. Clin Cancer Res 2001;7:3457-3464.
21. Davidson B, Reich R, Lazarovici P, et al. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 2003;9:2248-2259.
22. Davidson B, Reich R, Kopolovic J, et al. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis 2002;19:135-144.
23. Davidson B, Reich R, Lazarovici P, Flørenes VA, Nielsen S, Nesland JM. Altered expression and activation of the nerve growth factor receptors TrkA and p75 provides the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 2004;83:119-128.